A Randomized, Double-Blind, Placebo-controlled, Single-center, Phase 1 Inpatient Pilot Study to Explore the Safety and Efficacy of DAPAglifozin as Add-on to Day and Night Closed-loop Control in Patients Type 1 Diabetes (T1D)
Phase of Trial: Phase I
Latest Information Update: 06 Mar 2018
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- Acronyms DapaDream
- 28 Feb 2018 Status changed from recruiting to completed.
- 22 Mar 2017 Status changed from not yet recruiting to recruiting.
- 13 Dec 2016 New trial record